RE:Will this deal go through?We can't get a better deal at this time - M&A activity in pharma is trending down.
However I'm not as negative as BigBoy about the future of Aralez and i think it will end up around $2 or be one of the most undervalued pharma stock in N. America. The trajectory of growth suggests at least that and no matter what the economy is people need to purchase drugs. And as long as the organic growth is real and Yosprala get approved this year TRX will be fine. If we were in the glory days of pharma it would be a 5 bagger. Remember Aralez will no longer be on the venture. That alone will give it greater exposure and access to market capital.